A2 Academy Locks in 14 September San Francisco Trial Date for a $200 Million Sword Health Equity Suit — 2014 Acceleration Programme Reopens 11 Years On

The legal case A2 Academy, a United States startup mentoring vehicle formerly trading as Aging2.0, has built against Sword Health now has a calendar entry. According to filings reported by ECO on 15 June 2026, the United States District Court for the Northern District of California has scheduled jury selection and opening arguments in the suit for 14 September 2026 in San Francisco, ending two years of pre-trial skirmishing in a dispute that traces back to a 2014 acceleration programme contract for startups serving older Americans.

A2 Academy is asking the court to compel transfer of 5% of Sword Health's share capital. With the Porto-headquartered musculoskeletal-care unicorn most recently valued at roughly $4 billion, that stake would land in the neighbourhood of $200 million — a number the plaintiff arrived at by applying the contested equity percentage to the latest external valuation rather than any independent appraisal of the Delaware structure.

The plaintiff's theory of the case is that Sword Health (founded as Sword Health, Lda. in Portugal and re-domiciled into Delaware as Sword Health Inc.) never delivered the equity it had committed in writing under the 2014 programme. A2 also alleges that the founders concealed the creation of the United States parent in which the equity stake should have been issued, with the result that the eleven-year clock on potential claims was never properly started.

Sword's defence, summarised by founder and chief executive Virgílio Bento in remarks reported by ECO, leans on two pillars. First, the company argues the statute of limitations under California law has long since expired — the Delaware incorporation, it says, was a matter of public record and any reasonably diligent counterparty would have discovered it. Second, Bento told ECO he is "completamente confortável" (completely comfortable) that the outcome will land in Sword's favour, and the company has so far declined to settle.

For Portuguese investors and the broader Lisbon and Porto tech ecosystem, the trial is less about the dollar headline than about precedent. Sword Health is one of a small group of Portuguese-origin businesses to clear the unicorn threshold while keeping engineering and clinical operations rooted in Porto, and a court-ordered transfer of 5% — or even a forced settlement in that range — would compress the cap table at a moment when several Portuguese growth-stage companies are testing United States investors for the next funding cycle.

The case also tests how Portuguese-founded companies that re-incorporate into Delaware are treated when the original Portuguese-law contracts they signed at seed stage collide with subsequent United States corporate structuring. The 2014 acceleration agreement at the centre of the dispute pre-dates the Delaware re-domiciliation, and the court will have to decide whether the equity commitment travels with the brand or stays anchored to the legacy Portuguese entity.

A two-week trial window has been pencilled in. Both sides have indicated they will call founder-era witnesses, including programme administrators from the 2014 cohort. A verdict is not expected before the end of the third quarter, and any appeal would push the dispute well into 2027 — a timeline Sword's executive team will need to manage alongside its ongoing United States commercial expansion.